Streamlining Bioprocessing: Asahi Kasei Bioprocess Unveils the VANTIJ® SU-VFC Benchtop at BPI East
BOSTON — As the biopharmaceutical industry accelerates the development of complex modalities such as gene therapies, the pressure to optimize small-scale manufacturing has never been greater. Addressing this critical bottleneck, Asahi Kasei Bioprocess (AKB) has officially unveiled its latest innovation: the VANTIJ® SU-VFC (Single-Use Virus Filtration Controller) benchtop system. The launch, taking place this week at the Bioprocess International (BPI) East conference in Boston, marks a significant expansion of the company’s automation portfolio, promising to bridge the gap between laboratory-scale development and clinical-grade manufacturing.
Main Facts: A New Standard for Benchtop Filtration
The VANTIJ® SU-VFC benchtop system represents a strategic pivot toward user-centric design in the highly regulated field of viral clearance. Designed specifically for laboratory-scale and process development (PD) applications, the system is the latest addition to the VANTIJ® family, a line of products that has long been synonymous with precision in bioprocessing.
Key technical specifications and capabilities include:
- Scale Flexibility: The system is engineered to accommodate Planova™ 35N virus-removal filters in 0.12 m² or 0.3 m² configurations.
- Operational Simplicity: Recognizing the training burden in modern labs, the system features a guided "shadow-board" layout, which provides visual cues for assembly, effectively reducing the learning curve for operators.
- Ease of Maintenance: The instrument utilizes tool-free tube set installation and replacement, minimizing downtime and human error—a critical factor when working with expensive, therapy-specific drug substances.
- Integrated Software: The system operates via recipe-driven software that ensures consistency across batches, supporting robust data collection and automated batch reporting.
By combining these features, the VANTIJ® SU-VFC addresses the dual challenge of maintaining rigorous regulatory compliance while increasing throughput in the early stages of drug development.
Chronology: From Concept to Clinical Readiness
The development of the VANTIJ® platform did not occur in a vacuum. It is the culmination of years of feedback from bioprocess engineers grappling with the unique challenges of gene therapy manufacturing.
- Initial Design Phase: AKB identified that while large-scale manufacturing had benefited from significant automation, the "bottleneck" remained at the process development level. Operators were often forced to rely on manual, inconsistent setups for virus filtration, which risked product loss and regulatory delays.
- Product Engineering: Over the past 24 months, Asahi Kasei focused on "operator-focused design principles." The engineering team prioritized the reduction of complex connection points and the implementation of intuitive software interfaces.
- Validation and Testing: Before the public unveiling, the VANTIJ® SU-VFC underwent rigorous internal testing to ensure that its performance metrics matched the high standards of the broader Planova™ filter family, ensuring that developers could trust that their small-scale findings would be scalable to clinical production.
- The Boston Launch: The official debut at BPI East (September 22–25, 2026) serves as the industry’s first opportunity to interact with the hardware in a live environment, with demonstrations occurring at Booth 606.
Supporting Data: Why Virus Filtration Matters
In the realm of biopharmaceuticals—particularly those derived from mammalian cell cultures—viral clearance is a non-negotiable safety requirement. Regulatory bodies like the FDA and EMA mandate that manufacturers demonstrate the effective removal or inactivation of potential viral contaminants.
The use of Planova™ filters has long been a gold standard in this space. However, as the industry shifts toward "precision medicine," batch sizes are shrinking, and the cost of the therapeutic material is skyrocketing. A failed filtration step in a lab setting is no longer just a loss of time; it is a loss of precious, patient-specific material.
The VANTIJ® SU-VFC benchtop provides the process control necessary to mitigate these risks. By utilizing automated pressure control and integrated sensor arrays, the system ensures that filtration occurs within the optimal parameters defined by the manufacturer. This precision allows for higher product recovery rates—a metric that is increasingly being used to define the commercial viability of new gene therapies.
Official Responses and Strategic Vision
During the lead-up to the BPI East conference, leadership at Asahi Kasei Bioprocess emphasized that the VANTIJ® SU-VFC is more than just a piece of hardware; it is a solution to the "operational complexity" trap.
"The biopharmaceutical industry continues to pursue more efficient pathways for bringing innovative therapies to patients," stated Chris Rombach, President of Asahi Kasei Bioprocess America. "The VANTIJ® SU-VFC Benchtop reflects Asahi Kasei Bioprocess’s commitment to supporting manufacturers with solutions that simplify critical process steps."
Rombach further elaborated on the company’s broader mission. "Our fluid management business unit is dedicated to solving the fundamental tensions of the industry: safety, efficiency, and purity. Whether we are discussing our virus filtration technology, chromatography systems, or inline buffer formulation, our goal remains the same: to provide the infrastructure that allows our partners to advance GMP manufacturing without being bogged down by unnecessary process complexity."
The emphasis on "recipe-driven software" in the VANTIJ® system is particularly telling of the company’s strategic shift toward "Digitally Enabled Manufacturing." By allowing technicians to save and recall specific filtration protocols, the system reduces the variability introduced by different operators, thereby strengthening the data integrity packages that companies submit to regulatory agencies.
Implications for the Future of Gene Therapy
The launch of the VANTIJ® SU-VFC comes at a pivotal time for the gene therapy sector. As these therapies move from academic research into commercial manufacturing, the industry is struggling to scale up without losing the agility required for personalized treatments.
1. Reducing the Barrier to Entry
For many smaller biotech firms, the cost of entry for sophisticated manufacturing equipment can be prohibitive. By creating a benchtop system that mirrors the capabilities of larger, industrial-scale units, Asahi Kasei is enabling smaller labs to operate with "big pharma" quality standards. This lowers the risk of failure as a drug candidate transitions from PD to clinical manufacturing.
2. Addressing the Talent Gap
The biopharmaceutical industry faces a persistent shortage of highly trained process engineers. Equipment that is intuitive and "error-proof" helps compensate for this gap. The VANTIJ® system’s shadow-board design and tool-free installation mean that an operator does not need a decade of experience to achieve consistent, high-quality results.
3. Regulatory Speed
Regulatory agencies are increasingly demanding more data early in the process development lifecycle. The VANTIJ® system’s ability to generate automated batch reports provides a clear, audit-ready trail of evidence for how a product was processed. This documentation is vital for accelerating the time it takes for a therapy to receive clinical trial approval.
4. A New Ecosystem of Automation
The VANTIJ® family of products is indicative of a larger trend toward modular, single-use technology. As companies move away from stainless-steel, multi-use facilities, the demand for flexible, modular benchtop units will only increase. Asahi Kasei is positioning itself to be a cornerstone of this new modular ecosystem.
Conclusion: A Step Forward at BPI East
As the doors open at BPI East in Boston, the conversation surrounding the VANTIJ® SU-VFC will likely focus on its ability to solve the "last mile" of bioprocessing. By refining the way virus filtration is performed at the benchtop scale, Asahi Kasei Bioprocess is tackling one of the most critical, yet often overlooked, aspects of pharmaceutical production.
For researchers and process engineers, the VANTIJ® system represents a transition away from the "clunky" setups of the past and toward a future defined by precision, speed, and safety. As the industry continues to evolve, the ability to rapidly develop, validate, and scale these life-saving therapies will depend on the very equipment being showcased in Boston this week. Through a combination of intuitive engineering and deep industry expertise, Asahi Kasei appears ready to set a new benchmark for what is possible in the modern laboratory.
Attendees of BPI East are encouraged to visit Booth 606 through September 25th to witness the VANTIJ® SU-VFC in action and speak with the engineering team behind the platform.
